Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37733   clinical trials with a EudraCT protocol, of which   6184   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A phase II observer blind, randomised, controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine GSK 692342 when administered to adults aged 18 to 59 years with TB disease.

    Summary
    EudraCT number
    2012-001820-36
    Trial protocol
    EE  
    Global end of trial date
    10 Apr 2014

    Results information
    Results version number
    v2(current)
    This version publication date
    19 Mar 2016
    First version publication date
    22 May 2015
    Other versions
    v1
    Version creation reason
    • New data added to full data set
    Data for secondary endpoints have been added.

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    114886
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    Rue de l’Institut 89, Rixensart, Belgium, B-1330
    Public contact
    Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Interim
    Date of interim/final analysis
    20 Mar 2015
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    10 Apr 2014
    Global end of trial reached?
    Yes
    Global end of trial date
    10 Apr 2014
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To assess the safety and reactogenicity of GSK Biologicals’ candidate TB vaccine M72/AS01E in the study population.
    Protection of trial subjects
    All subjects were supervised after vaccination/product administration with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    14 Nov 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Estonia: 36
    Country: Number of subjects enrolled
    Taiwan: 106
    Worldwide total number of subjects
    142
    EEA total number of subjects
    36
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    142
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    During the screening the following was performed: informed consent was obtained and signed from parents or guardians of subjects, check for inclusion/exclusion criteria and contraindications/precautions was performed, and medical history of subjects was collected. Prior to vaccination, subjects’ pre-vaccination body temperature was evaluated.

    Period 1
    Period 1 title
    Overall study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Carer
    Blinding implementation details
    During the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoints have been unaware of which vaccine was administered.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    TB Treatment GSK 692342 Group
    Arm description
    Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.
    Arm type
    Experimental

    Investigational medicinal product name
    GSK 692342
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Two doses of vaccine were administered intramuscularly in the deltoid region of the arm, on a 0, 1 Months schedule

    Arm title
    TB Treatment Saline Group
    Arm description
    Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.
    Arm type
    Placebo

    Investigational medicinal product name
    Physiological Saline
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Doses were administered intramuscularly in the deltoid of the arm at Months 0 and 1

    Arm title
    TB Treated GSK 692342 Group
    Arm description
    Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1
    Arm type
    Experimental

    Investigational medicinal product name
    GSK 692342
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Two doses of vaccine were administered intramuscularly in the deltoid region of the arm, on a 0, 1 Months schedule

    Arm title
    TB Treated Saline Group
    Arm description
    Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.
    Arm type
    Placebo

    Investigational medicinal product name
    Physiological Saline
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Doses were administered intramuscularly in the deltoid of the arm at Months 0 and 1

    Arm title
    TB Naive GSK 692342 Group
    Arm description
    Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.
    Arm type
    Experimental

    Investigational medicinal product name
    GSK 692342
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Two doses of vaccine were administered intramuscularly in the deltoid region of the arm, on a 0, 1 Months schedule

    Arm title
    TB Naive Saline Group
    Arm description
    Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.
    Arm type
    Placebo

    Investigational medicinal product name
    Physiological Saline
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Doses were administered intramuscularly in the deltoid of the arm at Months 0 and 1

    Number of subjects in period 1
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Started
    7
    6
    24
    25
    40
    40
    Completed
    6
    5
    22
    25
    40
    40
    Not completed
    1
    1
    2
    0
    0
    0
         Consent withdrawn by subject
    1
    1
    1
    -
    -
    -
         Lost to follow-up
    -
    -
    1
    -
    -
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    TB Treatment GSK 692342 Group
    Reporting group description
    Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Treatment Saline Group
    Reporting group description
    Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Treated GSK 692342 Group
    Reporting group description
    Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1

    Reporting group title
    TB Treated Saline Group
    Reporting group description
    Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Naive GSK 692342 Group
    Reporting group description
    Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Naive Saline Group
    Reporting group description
    Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Reporting group values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group Total
    Number of subjects
    7 6 24 25 40 40 142
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    42.9 ± 11.5 44.7 ± 11.8 44.5 ± 10.3 47 ± 9.8 33.8 ± 8.5 33.3 ± 9.8 -
    Gender categorical
    Units: Subjects
        Female
    1 2 13 7 16 21 60
        Male
    6 4 11 18 24 19 82

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    TB Treatment GSK 692342 Group
    Reporting group description
    Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Treatment Saline Group
    Reporting group description
    Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Treated GSK 692342 Group
    Reporting group description
    Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1

    Reporting group title
    TB Treated Saline Group
    Reporting group description
    Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Naive GSK 692342 Group
    Reporting group description
    Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Naive Saline Group
    Reporting group description
    Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Primary: Number of subjects with solicited local symptoms

    Close Top of page
    End point title
    Number of subjects with solicited local symptoms [1]
    End point description
    End point type
    Primary
    End point timeframe
    During the 7 day (Days 0-6), after each vaccine dose
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    7
    6
    24
    25
    40
    40
    Units: Subjects
        Pain, D1 (N=7,6,24,25,40,40)
    6
    1
    21
    2
    38
    5
        Redness, D1 (N=7,6,24,25,40,40)
    2
    0
    4
    0
    7
    0
        Swelling, D1 (N=7,6,24,25,40,40)
    2
    0
    5
    1
    4
    0
        Pain, D2 (N=6,5,21,25,39,39)
    5
    1
    19
    1
    36
    6
        Redness, D2 (N=6,5,21,25,39,39)
    3
    0
    7
    0
    6
    0
        Swelling, D2 (N=6,5,21,25,39,39)
    3
    0
    4
    0
    11
    0
        Pain, Across (N=7,6,24,25,40,40)
    6
    1
    22
    3
    39
    8
        Redness, Across (N=7,6,24,25,40,40)
    3
    0
    8
    0
    10
    0
        Swelling, Across (N=7,6,24,25,40,40)
    3
    0
    6
    1
    11
    0
    No statistical analyses for this end point

    Primary: Number of subjects with solicited general symptoms

    Close Top of page
    End point title
    Number of subjects with solicited general symptoms [2]
    End point description
    End point type
    Primary
    End point timeframe
    During the 7 day (Days 0-6), after each vaccine dose
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    7
    6
    24
    25
    40
    40
    Units: Subjects
        Fatigue, D1 (N=7,6,24,25,40,40)
    1
    2
    14
    6
    19
    8
        Gastrointestinal symptoms, D1 (N=7,6,24,25,40,40)
    0
    0
    4
    2
    5
    5
        Headache, D1 (N=7,6,24,25,40,40)
    1
    0
    11
    4
    8
    5
        Malaise, D1 (N=7,6,24,25,40,40)
    1
    1
    11
    2
    14
    8
        Myalgia, D1 (N=7,6,24,25,40,40)
    2
    0
    13
    4
    24
    7
        Temperature/(Axillary), D1 (N=7,6,24,25,40,40)
    0
    0
    1
    0
    2
    0
        Fatigue, D2 (N=6,5,21,25,39,39)
    3
    1
    13
    5
    33
    7
        Gastrointestinal symptoms, D2 (N=6,5,21,25,39,39)
    2
    0
    7
    3
    13
    3
        Headache, D2 (N=6,5,21,25,39,39)
    3
    1
    12
    2
    22
    3
        Malaise, D2 (N=6,5,21,25,39,39)
    3
    2
    11
    5
    32
    3
        Myalgia, D2 (N=6,5,21,25,39,39)
    3
    1
    14
    4
    28
    3
        Temperature/(Axillary), D2 (N=6,5,21,25,39,39)
    4
    1
    9
    0
    16
    0
        Fatigue, Across (N=7,6,24,25,40,40)
    3
    2
    17
    8
    36
    10
        Gastrointestinal symptoms, Across (N=7,6,24,25,40,
    2
    0
    10
    4
    16
    6
        Headache, Across (N=7,6,24,25,40,40)
    3
    1
    18
    4
    24
    6
        Malaise, Across (N=7,6,24,25,40,40)
    3
    2
    16
    6
    35
    9
        Myalgia, Across (N=7,6,24,25,40,40)
    3
    1
    18
    5
    34
    7
        Temperature/(Axillary), Across (N=7,6,24,25,40,40)
    4
    1
    10
    0
    17
    0
    No statistical analyses for this end point

    Primary: Number of subjects with adverse events (AEs)

    Close Top of page
    End point title
    Number of subjects with adverse events (AEs) [3]
    End point description
    End point type
    Primary
    End point timeframe
    During the 30 day (Days 0-29) after vaccination
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    7
    6
    24
    25
    40
    40
    Units: Subjects
        Any AEs
    1
    2
    14
    7
    19
    8
    No statistical analyses for this end point

    Primary: Number of subjects with serious adverse events (SAEs)

    Close Top of page
    End point title
    Number of subjects with serious adverse events (SAEs) [4]
    End point description
    End point type
    Primary
    End point timeframe
    Up to day 210
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    7
    6
    24
    25
    40
    40
    Units: Subjects
        Any SAEs
    0
    0
    2
    2
    1
    0
    No statistical analyses for this end point

    Secondary: Number of subjects with anti-mycobacterium tuberculosis fusion protein M72 antibodies.

    Close Top of page
    End point title
    Number of subjects with anti-mycobacterium tuberculosis fusion protein M72 antibodies.
    End point description
    Cut-off values assessed were greater than or equal to 2.8 measured by ELISA (Enzyme Linked Immunosorbent Assay) in the sera of subjects seronegative before vaccination.
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Day 30 – D30), post-dose 2 (Days 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    7
    4
    21
    25
    38
    39
    Units: Subjects
        Anti-M72, PRE (N=7; 4; 21; 25; 37; 39)
    0
    0
    0
    0
    1
    2
        Anti-M72, D30 (N=6; 4; 21; 25; 38; 39)
    5
    0
    19
    0
    26
    2
        Anti-M72, D60 (N=6; 3; 19; 25; 38; 39)
    6
    0
    18
    0
    37
    3
        Anti-M72, D210 (N=6; 3; 19; 25; 38; 39)
    6
    0
    18
    0
    38
    1
    No statistical analyses for this end point

    Secondary: Concentrations of mycobacterium tuberculosis fusion protein M72.

    Close Top of page
    End point title
    Concentrations of mycobacterium tuberculosis fusion protein M72.
    End point description
    Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL)
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Day 30 – D30), post-dose 2 (Days 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    7
    4
    21
    25
    38
    39
    Units: EU/mL
    geometric mean (confidence interval 95%)
        Anti-M72, PRE (N=7; 4; 21; 25; 37; 39)
    1.4 (1.4 to 1.4)
    1.4 (1.4 to 1.4)
    1.4 (1.4 to 1.4)
    1.4 (1.4 to 1.4)
    1.4 (1.4 to 1.5)
    1.5 (1.4 to 1.6)
        Anti-M72, D30 (N=6; 4; 21; 25; 38; 39)
    6.7 (2.1 to 21)
    1.4 (1.4 to 1.4)
    11.7 (6.3 to 22)
    1.4 (1.4 to 1.4)
    4.5 (3.3 to 6.2)
    1.5 (1.4 to 1.6)
        Anti-M72, D60 (N=6; 3; 19; 25; 38; 39)
    206.6 (46.2 to 923.2)
    1.4 (1.4 to 1.4)
    226.2 (99 to 517.2)
    1.4 (1.4 to 1.4)
    248.6 (171 to 361.4)
    1.7 (1.3 to 2.3)
        Anti-M72, D210 (N=6; 3; 19; 25; 38; 39)
    38.4 (18.9 to 77.9)
    1.4 (1.4 to 1.4)
    50.9 (27.3 to 94.8)
    1.4 (1.4 to 1.4)
    45.6 (34.2 to 60.8)
    1.4 (1.4 to 1.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of the different immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of the different immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD4-ALL doubles, PRE (N=4; 3; 15; 22; 30; 30)
    247 (204.5 to 333.5)
    178 (70 to 651)
    347 (196 to 523)
    549.5 (375 to 997)
    286 (173 to 471)
    352 (170 to 579)
        CD4-ALL doubles, D7 (N=4; 3; 13; 15; 26; 28)
    997.5 (714 to 1345)
    182 (82 to 431)
    1097 (985 to 1760)
    469 (328 to 1075)
    801.5 (440 to 1492)
    265.5 (167.5 to 571.5)
        CD4-ALL doubles, D30 (N=5; 2; 16; 16; 34; 34)
    2959 (1289 to 2989)
    730 (216 to 1244)
    2616.5 (1417 to 5614)
    466 (261.5 to 1145.5)
    1228.5 (941 to 2131)
    312.5 (202 to 726)
        CD4-ALL doubles, D37 (N=5; 3; 18; 19; 34; 34)
    4433 (3024 to 10010)
    273 (221 to 445)
    5705.5 (2219 to 11228)
    533 (227 to 1235)
    5987.5 (3987 to 9605)
    247 (175 to 387)
        CD4-ALL doubles, D60 (N=4; 2; 15; 18; 31; 32)
    5648 (3686 to 7957)
    241 (224 to 258)
    2072 (1083 to 4199)
    517 (352 to 1242)
    5153 (2884 to 8978)
    240 (146 to 476)
        CD4-ALL doubles, D210 (N=6; 3; 13; 17; 37; 36)
    2922.5 (967 to 4411)
    118 (116 to 307)
    1154 (1028 to 1808)
    445 (243 to 734)
    2155 (1389 to 4160)
    254 (166 to 383)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing 2 or more immune markers among 6.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing 2 or more immune markers among 6.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    16
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD4-At least 2, PRE (N=4; 3; 15; 22; 30; 30)
    260 (217.5 to 346.5)
    207 (96 to 687)
    364 (238 to 536)
    562.5 (402 to 1010)
    325 (240 to 512)
    365 (214 to 609)
        CD4- At least 2, D7 (N=4; 3; 13; 15; 26; 28)
    1010.5 (733.5 to 1358)
    208 (95 to 457)
    1152 (1011 to 1895)
    482 (347 to 1088)
    856 (479 to 1505)
    278.5 (193.5 to 600)
        CD4- At least 2, D30 (N=5; 2; 16; 16; 34; 34)
    2972 (1302 to 3002)
    765 (229 to 1301)
    2636 (1437 to 5655)
    497 (282 to 1179)
    1248.5 (954 to 2144)
    348.5 (238 to 754)
        CD4- At least 2, D37 (N=5; 3; 18; 19; 34; 34)
    4446 (3037 to 10107)
    316 (234 to 458)
    5733.5 (2232 to 11281)
    565 (260 to 1262)
    6051.5 (4191 to 9679)
    277.5 (190 to 425)
        CD4- At least 2, D60 (N=4; 2; 15; 18; 31; 32)
    5661 (3699 to 7976.5)
    254 (237 to 271)
    2101 (1115 to 4275)
    583 (378 to 1256)
    5185 (2897 to 9031)
    258 (160.5 to 496)
        CD4- At least 2, D210 (N=6; 3; 13; 17; 37; 36)
    2948.5 (993 to 4670)
    131 (129 to 320)
    1167 (1041 to 1821)
    480 (298 to 770)
    2269 (1419 to 4173)
    299 (201.5 to 449.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L+/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)
    106.5 (68 to 134)
    4 (4 to 252)
    87 (34 to 140)
    124 (74 to 186)
    60 (4 to 108)
    54 (17 to 142)
        CD40L+/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)
    267.5 (218.5 to 493.5)
    42 (4 to 241)
    329 (140 to 454)
    84 (25 to 154)
    87 (24 to 229)
    55.5 (4 to 132)
        CD40L+/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)
    1066 (261 to 1233)
    330.5 (33 to 628)
    776 (341 to 1070.5)
    71 (30.5 to 161.5)
    89.5 (37 to 287)
    47 (17 to 157)
        CD40L+/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)
    1186 (1084 to 1403)
    80 (44 to 158)
    897.5 (333 to 1123)
    87 (52 to 135)
    436.5 (192 to 592)
    45 (11 to 106)
        CD40L+/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)
    1444 (1039 to 1615.5)
    4 (4 to 4)
    417 (87 to 815)
    132 (73 to 171)
    436 (219 to 826)
    31 (4 to 130.5)
        CD40L+/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)
    585.5 (288 to 997)
    18 (4 to 74)
    288 (217 to 313)
    68 (38 to 157)
    201 (95 to 504)
    35.5 (18 to 89.5)
        CD40L+/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)
    12 (4 to 22)
    55 (4 to 93)
    25 (4 to 48)
    20.5 (4 to 58)
    4 (4 to 26)
    4 (4 to 33)
        CD40L+/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)
    33 (17 to 44)
    17 (4 to 45)
    44 (31 to 116)
    27 (4 to 34)
    19 (4 to 54)
    16.5 (4 to 34)
        CD40L+/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)
    204 (162 to 213)
    48 (4 to 92)
    250 (149.5 to 370.5)
    16 (4 to 43)
    279.5 (144 to 385)
    20.5 (4 to 50)
        CD40L+/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)
    436 (246 to 550)
    35 (31 to 49)
    292 (154 to 525)
    9 (4 to 43)
    558.5 (250 to 884)
    4.5 (4 to 37)
        CD40L+/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)
    654 (561.5 to 1140.5)
    28 (24 to 32)
    301 (183 to 458)
    19 (4 to 42)
    1117 (551 to 1690)
    20 (4 to 33)
        CD40L+/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)
    448 (202 to 552)
    4 (4 to 5)
    148 (116 to 209)
    18 (4 to 31)
    566 (245 to 997)
    4 (4 to 27.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L+/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 11)
    4 (4 to 26)
    4 (4 to 23)
    17 (4 to 31)
    4 (4 to 27)
    12.5 (4 to 34)
        CD40L+/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)
    33 (12 to 50.5)
    4 (4 to 47)
    40 (31 to 103)
    4 (4 to 19)
    32.5 (4 to 84)
    4 (4 to 27.5)
        CD40L+/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)
    48 (47 to 117)
    25.5 (4 to 47)
    82.5 (39 to 116)
    4 (4 to 18.5)
    39.5 (25 to 76)
    17 (4 to 37)
        CD40L+/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)
    118 (89 to 307)
    4 (4 to 19)
    133.5 (42 to 242)
    4 (4 to 20)
    278 (161 to 525)
    17 (4 to 47)
        CD40L+/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)
    151.5 (129.5 to 246)
    32 (4 to 60)
    75 (44 to 236)
    4 (4 to 18)
    269 (128 to 500)
    4 (4 to 28.5)
        CD40L+/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)
    112.5 (31 to 218)
    18 (4 to 60)
    47 (24 to 95)
    4 (4 to 29)
    126 (61 to 296)
    10.5 (4 to 40)
        CD40L+/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)
    11.5 (4 to 41)
    4 (4 to 17)
    14 (4 to 22)
    17.5 (4 to 45)
    19.5 (4 to 37)
    4 (4 to 24)
        CD40L+/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)
    45.5 (4 to 88)
    4 (4 to 17)
    43 (17 to 75)
    4 (4 to 46)
    44.5 (4 to 69)
    5 (4 to 49.5)
        CD40L+/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)
    102 (32 to 201)
    84.5 (33 to 136)
    150.5 (69 to 253.5)
    25 (4 to 53)
    300 (202 to 519)
    18 (4 to 49)
        CD40L+/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)
    263 (94 to 305)
    20 (4 to 65)
    182 (67 to 393)
    4 (4 to 29)
    732 (498 to 946)
    4 (4 to 16)
        CD40L+/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)
    381.5 (223.5 to 561.5)
    46.5 (32 to 61)
    171 (84 to 514)
    4 (4 to 38)
    939 (534 to 1537)
    17.5 (4 to 30)
        CD40L+/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)
    166.5 (66 to 380)
    18 (4 to 31)
    126 (101 to 148)
    17 (4 to 32)
    453 (281 to 768)
    11 (4 to 37)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L+/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)
    67 (47 to 74.5)
    55 (4 to 161)
    61 (19 to 218)
    188.5 (66 to 272)
    48.5 (17 to 101)
    44.5 (19 to 164)
        CD40L+/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)
    270.5 (224 to 408.5)
    4 (4 to 73)
    389 (207 to 735)
    151 (79 to 278)
    232 (46 to 491)
    43 (10.5 to 148.5)
        CD40L+/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)
    563 (541 to 1023)
    115 (4 to 226)
    902 (397.5 to 2177)
    132.5 (54.5 to 398)
    156.5 (76 to 481)
    71.5 (18 to 221)
        CD40L+/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)
    1236 (886 to 3361)
    4 (4 to 111)
    1828 (462 to 3273)
    253 (45 to 463)
    738.5 (422 to 1663)
    46.5 (17 to 114)
        CD40L+/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)
    2219.5 (1183 to 3234)
    24.5 (4 to 45)
    608 (361 to 1433)
    149.5 (97 to 340)
    560 (192 to 1563)
    55.5 (25.5 to 150)
        CD40L+/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)
    869 (202 to 1422)
    32 (4 to 33)
    439 (218 to 620)
    174 (46 to 248)
    301 (137 to 602)
    22 (4 to 137)
        CD40L+/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)
    10 (4 to 20.5)
    20 (4 to 73)
    8 (4 to 38)
    18 (4 to 43)
    9.5 (4 to 47)
    20 (4 to 52)
        CD40L+/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)
    34 (18 to 40.5)
    17 (4 to 47)
    58 (24 to 74)
    4 (4 to 31)
    40.5 (17 to 98)
    4 (4 to 41)
        CD40L+/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)
    132 (45 to 150)
    25.5 (4 to 47)
    152.5 (79 to 215)
    25.5 (4 to 52.5)
    125.5 (71 to 216)
    17 (4 to 28)
        CD40L+/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)
    276 (117 to 889)
    37 (4 to 87)
    375.5 (230 to 805)
    40 (4 to 84)
    915 (471 to 1575)
    18 (4 to 38)
        CD40L+/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)
    359.5 (255 to 556.5)
    62.5 (4 to 121)
    176 (75 to 327)
    26 (4 to 65)
    792 (421 to 1060)
    4 (4 to 38.5)
        CD40L+/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)
    167 (75 to 191)
    19 (4 to 35)
    77 (23 to 134)
    4 (4 to 40)
    272 (142 to 358)
    18 (4 to 34.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L+/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)
    10.5 (4 to 40)
    17 (4 to 20)
    25 (6 to 61)
    43 (4 to 80)
    27.5 (4 to 54)
    12 (4 to 60)
        CD40L+/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)
    113.5 (62.5 to 155.5)
    4 (4 to 31)
    227 (65 to 469)
    22 (4 to 71)
    163 (100 to 239)
    29.5 (4 to 54)
        CD40L+/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)
    71 (60 to 75)
    41 (32 to 50)
    124.5 (64.5 to 284)
    13.5 (4 to 65)
    86.5 (27 to 154)
    30 (4 to 59)
        CD40L+/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)
    406 (406 to 1923)
    5 (4 to 31)
    649 (245 to 1982)
    17 (4 to 72)
    1355.5 (917 to 2882)
    19 (4 to 58)
        CD40L+/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)
    213 (75 to 378.5)
    17.5 (4 to 31)
    147 (58 to 339)
    20.5 (4 to 46)
    399 (135 to 664)
    4 (4 to 35.5)
        CD40L+/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)
    129 (18 to 304)
    4 (4 to 73)
    57 (37 to 115)
    32 (4 to 62)
    107 (65 to 180)
    30.5 (5 to 48)
        CD40L+/IL2-/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)
    4 (4 to 98.5)
    103 (4 to 244)
    19 (4 to 41)
    10.5 (4 to 73)
    4 (4 to 29)
    4 (4 to 32)
        CD40L+/IL2-/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)
    4 (4 to 10.5)
    4 (4 to 506)
    14 (4 to 83)
    4 (4 to 23)
    19 (4 to 171)
    4 (4 to 41.5)
        CD40L+/IL2-/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)
    4 (4 to 18)
    1375.5 (4 to 2747)
    208 (11 to 689)
    4 (4 to 37)
    342 (133 to 769)
    4 (4 to 136)
        CD40L+/IL2-/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)
    973 (17 to 1644)
    213 (20 to 373)
    1544 (787 to 2630)
    18 (4 to 200)
    3575.5 (2450 to 6212)
    4 (4 to 32)
        CD40L+/IL2-/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)
    4 (4 to 373.5)
    4 (4 to 4)
    168 (4 to 727)
    4 (4 to 104)
    1426 (653 to 2820)
    4 (4 to 89)
        CD40L+/IL2-/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)
    10.5 (4 to 712)
    4 (4 to 4)
    296 (13 to 743)
    45 (4 to 233)
    497 (34 to 900)
    4 (4 to 89.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L-/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 26)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)
    4 (4 to 68)
    4 (4 to 17)
    19 (4 to 74)
    4 (4 to 18)
    4 (4 to 26)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 41)
    26 (4 to 48)
    35 (4 to 85)
    4 (4 to 10.5)
    4 (4 to 25)
    4 (4 to 19)
        CD40L-/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)
    89 (46 to 93)
    4 (4 to 4)
    64.5 (17 to 148)
    4 (4 to 4)
    32.5 (4 to 66)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)
    39.5 (17.5 to 62.5)
    4 (4 to 4)
    4 (4 to 60)
    4 (4 to 4)
    19 (4 to 33)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)
    19 (4 to 32)
    4 (4 to 4)
    4 (4 to 19)
    4 (4 to 4)
    4 (4 to 31)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)
    4 (4 to 11)
    4 (4 to 4)
    4 (4 to 20)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)
    17 (4 to 17)
    4 (4 to 4)
    19.5 (4 to 54.5)
    4 (4 to 17.5)
    17.5 (4 to 33)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 24)
    4 (4 to 4)
    34 (8 to 67)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)
    21 (10.5 to 55.5)
    4 (4 to 4)
    4 (4 to 19)
    4 (4 to 4)
    45 (16 to 79)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)
    4 (4 to 21)
    17 (4 to 18)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 34)
    4 (4 to 10.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L-/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)
    4 (4 to 16.5)
    4 (4 to 4)
    17 (4 to 18)
    4 (4 to 4)
    4 (4 to 19)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    11 (4 to 23.5)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)
    17 (17 to 32)
    4 (4 to 4)
    17 (4 to 24)
    4 (4 to 4)
    19.5 (4 to 61)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 20)
    4 (4 to 4)
    4 (4 to 22)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)
    4 (4 to 24)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)
    4 (4 to 10.5)
    4 (4 to 20)
    4 (4 to 23)
    4 (4 to 18)
    4 (4 to 4)
    4 (4 to 21)
        CD40L-/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)
    4 (4 to 18)
    4 (4 to 17)
    4 (4 to 17)
    17 (4 to 30)
    18.5 (4 to 26)
    4 (4 to 12)
        CD40L-/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)
    30 (19 to 32)
    4 (4 to 4)
    21 (6.5 to 44.5)
    4 (4 to 19)
    18 (4 to 32)
    4 (4 to 20)
        CD40L-/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    27.5 (17 to 45)
    4 (4 to 5)
    40.5 (19 to 82)
    4 (4 to 20)
        CD40L-/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)
    11 (4.5 to 28.5)
    17.5 (4 to 31)
    4 (4 to 20)
    11 (4 to 23)
    49 (20 to 70)
    4 (4 to 18)
        CD40L-/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)
    17.5 (4 to 59)
    4 (4 to 32)
    4 (4 to 17)
    4 (4 to 26)
    25 (8 to 44)
    4 (4 to 19.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L-/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)
    10.5 (4 to 25)
    4 (4 to 4)
    24 (4 to 59)
    13.5 (4 to 136)
    17.5 (4 to 32)
    4 (4 to 57)
        CD40L-/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)
    53.5 (34.5 to 87.5)
    4 (4 to 17)
    102 (40 to 230)
    18 (4 to 234)
    53 (17 to 246)
    4 (4 to 53)
        CD40L-/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)
    76 (4 to 117)
    26 (4 to 48)
    112 (21.5 to 212)
    44 (10.5 to 334.5)
    42 (4 to 89)
    20 (4 to 46)
        CD40L-/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)
    246 (116 to 288)
    34 (4 to 65)
    212.5 (94 to 698)
    50 (5 to 361)
    185.5 (61 to 463)
    4 (4 to 33)
        CD40L-/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)
    162.5 (76 to 214)
    14 (4 to 24)
    34 (19 to 338)
    46 (4 to 534)
    69 (32 to 277)
    18.5 (4 to 45.5)
        CD40L-/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)
    19.5 (4 to 156)
    4 (4 to 18)
    30 (18 to 112)
    29 (4 to 169)
    46 (4 to 77)
    11.5 (4 to 38)
        CD40L-/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)
    11.5 (5 to 31)
    18 (18 to 29)
    20 (4 to 55)
    4 (4 to 41)
    8 (4 to 38)
    22.5 (4 to 68)
        CD40L-/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)
    25.5 (11 to 38)
    17 (4 to 45)
    19 (4 to 75)
    17 (4 to 32)
    26 (4 to 57)
    28.5 (4 to 81.5)
        CD40L-/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)
    21 (6 to 26)
    4 (4 to 4)
    51.5 (15 to 101)
    32.5 (4.5 to 67)
    8 (4 to 61)
    12.5 (4 to 31)
        CD40L-/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)
    46 (31 to 153)
    66 (31 to 117)
    87 (31 to 256)
    11 (4 to 119)
    309 (137 to 532)
    7.5 (4 to 26)
        CD40L-/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)
    67 (57.5 to 108)
    50 (40 to 60)
    23 (4 to 104)
    36 (4 to 59)
    88 (35 to 225)
    22 (4 to 44)
        CD40L-/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)
    4 (4 to 60)
    4 (4 to 4)
    5 (4 to 57)
    23 (4 to 54)
    24 (4 to 76)
    4 (4 to 34.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD4+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L-/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)
    17.5 (4 to 52.5)
    20 (4 to 61)
    47 (4 to 64)
    51 (4 to 99)
    70 (38 to 157)
    14.5 (4 to 85)
        CD40L-/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)
    69.5 (17.5 to 114)
    4 (4 to 83)
    59 (12 to 363)
    46 (6 to 482)
    78 (32 to 248)
    25.5 (4 to 76)
        CD40L-/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)
    45 (45 to 61)
    4 (4 to 4)
    52 (4 to 201.5)
    33.5 (4 to 270)
    47 (4 to 138)
    26.5 (4 to 132)
        CD40L-/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)
    191 (89 to 408)
    34 (31 to 97)
    273 (131 to 720)
    27 (4 to 261)
    495.5 (267 to 1466)
    19 (4 to 86)
        CD40L-/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)
    14.5 (4 to 48.5)
    4 (4 to 4)
    32 (4 to 267)
    51.5 (17 to 144)
    129 (40 to 276)
    19.5 (4 to 84)
        CD40L-/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)
    53.5 (31 to 117)
    4 (4 to 60)
    30 (4 to 85)
    34 (4 to 92)
    31 (4 to 126)
    55 (32.5 to 115)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing at least 2 immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing at least 2 immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD8-ALL doubles, PRE (N=4; 3; 15; 22; 30; 30)
    93 (63.5 to 269)
    44 (44 to 135)
    99 (75 to 159)
    110.5 (59 to 326)
    73 (44 to 144)
    69.5 (44 to 132)
        CD8-ALL doubles, D7 (N=4; 3; 13; 15; 26; 28)
    94.5 (80.5 to 141)
    72 (45 to 77)
    222 (146 to 329)
    62 (44 to 324)
    74.5 (44 to 144)
    92.5 (53 to 191)
        CD8-ALL doubles, D30 (N=5; 2; 16; 16; 34; 34)
    44 (44 to 64)
    81.5 (44 to 119)
    243 (101 to 385)
    153.5 (75.5 to 1064)
    80 (44 to 150)
    77.5 (59 to 172)
        CD8-ALL doubles, D37 (N=5; 3; 18; 19; 34; 34)
    126 (118 to 134)
    76 (44 to 93)
    347 (97 to 604)
    108 (59 to 295)
    72.5 (57 to 149)
    75.5 (44 to 140)
        CD8-ALL doubles, D60 (N=4; 2; 15; 18; 31; 32)
    85.5 (55.5 to 233)
    118 (69 to 167)
    189 (60 to 367)
    161 (84 to 491)
    96 (44 to 245)
    71 (44 to 157.5)
        CD8-ALL doubles, D210 (N=6; 3; 13; 17; 37; 36)
    347.5 (170 to 572)
    78 (44 to 91)
    259 (61 to 312)
    119 (44 to 390)
    110 (69 to 248)
    71.5 (49.5 to 233)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing 2 or more immune markers among 6.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing 2 or more immune markers among 6.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD8-At least 2, PRE (N=4; 3; 15; 22; 30; 30)
    106 (76.5 to 282)
    57 (57 to 148)
    143 (88 to 172)
    151.5 (81 to 339)
    96 (57 to 157)
    85.5 (57 to 169)
        CD8- At least 2, D7 (N=4; 3; 13; 15; 26; 28)
    107.5 (93.5 to 154)
    85 (58 to 90)
    245 (159 to 369)
    75 (57 to 337)
    116 (71 to 158)
    124 (88 to 232)
        CD8- At least 2, D30 (N=5; 2; 16; 16; 34; 34)
    57 (57 to 77)
    109 (86 to 132)
    256 (114 to 410.5)
    166.5 (88.5 to 1077)
    96 (73 to 163)
    106.5 (77 to 198)
        CD8- At least 2, D37 (N=5; 3; 18; 19; 34; 34)
    139 (131 to 147)
    89 (57 to 106)
    362 (110 to 617)
    121 (72 to 308)
    85.5 (70 to 162)
    103.5 (58 to 161)
        CD8- At least 2, D60 (N=4; 2; 15; 18; 31; 32)
    98.5 (68.5 to 246)
    131 (82 to 180)
    202 (89 to 380)
    174 (97 to 504)
    111 (76 to 270)
    106.5 (57 to 191)
        CD8- At least 2, D210 (N=6; 3; 13; 17; 37; 36)
    403.5 (183 to 585)
    91 (57 to 151)
    272 (74 to 379)
    133 (76 to 403)
    137 (83 to 291)
    124.5 (81.5 to 292)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L+/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)
    4 (4 to 14)
    4 (4 to 4)
    4 (4 to 62)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 25)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)
    4 (4 to 41)
    4 (4 to 4)
    4 (4 to 48)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)
    58 (4 to 99)
    4 (4 to 38)
    4 (4 to 4)
    4 (4 to 33)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)
    4 (4 to 19)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)
    35 (4 to 46)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 25)
    4 (4 to 4)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L+/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 32)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)
    4 (4 to 4)
    14 (4 to 24)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L+/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 33.5)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 23)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 55)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    36.5 (4 to 84)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 168)
    4 (4 to 21)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 42)
    4 (4 to 24)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)
    4 (4 to 13)
    4 (4 to 51)
    4 (4 to 56)
    4 (4 to 4)
    4 (4 to 21)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 37)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 17)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)
    4 (4 to 21)
    24.5 (4 to 45)
    4 (4 to 20)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L+/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 21)
    4 (4 to 4)
    4 (4 to 19)
    4 (4 to 9)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L+/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 23.5)
    4 (4 to 26)
    4 (4 to 5)
    4 (4 to 4)
    4 (4 to 26)
    4 (4 to 18)
        CD40L+/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 54)
    4 (4 to 22)
    4 (4 to 24)
    4 (4 to 4.5)
        CD40L+/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    41.5 (4 to 79)
    4 (4 to 4)
    4 (4 to 28.5)
    4 (4 to 25)
    4 (4 to 31)
        CD40L+/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 36)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 21)
    4 (4 to 23)
        CD40L+/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)
    4 (4 to 21)
    16.5 (4 to 29)
    4 (4 to 4)
    14.5 (4 to 46)
    4 (4 to 76)
    4 (4 to 14.5)
        CD40L+/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)
    19.5 (4 to 88)
    4 (4 to 4)
    4 (4 to 35)
    4 (4 to 4)
    4 (4 to 29)
    4 (4 to 34.5)
        CD40L+/IL2-/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)
    97.5 (4 to 412)
    143 (4 to 178)
    29 (4 to 203)
    4 (4 to 139)
    7.5 (4 to 130)
    25 (4 to 222)
        CD40L+/IL2-/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)
    33.5 (4 to 68)
    110 (93 to 390)
    4 (4 to 4)
    4 (4 to 413)
    4 (4 to 183)
    26 (4 to 164)
        CD40L+/IL2-/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)
    73 (4 to 113)
    161 (83 to 239)
    4 (4 to 23)
    4 (4 to 78.5)
    4 (4 to 71)
    99.5 (4 to 288)
        CD40L+/IL2-/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)
    4 (4 to 203)
    4 (4 to 216)
    4 (4 to 293)
    43 (4 to 125)
    4 (4 to 127)
    13.5 (4 to 213)
        CD40L+/IL2-/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)
    18.5 (4 to 163.5)
    44.5 (4 to 85)
    101 (4 to 345)
    85 (4 to 270)
    61 (4 to 153)
    36.5 (4 to 214)
        CD40L+/IL2-/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)
    53 (15 to 92)
    122 (4 to 202)
    333 (4 to 583)
    121 (4 to 249)
    22 (4 to 311)
    33.5 (4 to 302.5)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L-/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)
    4 (4 to 15.5)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L-/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 41)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 5)
        CD40L-/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)
    4 (4 to 4)
    4 (4 to 37)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 20)
    4 (4 to 23.5)
        CD40L-/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 32)
    4 (4 to 4)
    4 (4 to 19)
    4 (4 to 4)
        CD40L-/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)
    28 (4 to 49)
    4 (4 to 4)
    4 (4 to 6)
    4 (4 to 4)
    4 (4 to 18)
    4 (4 to 28)
        CD40L-/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)
    4 (4 to 15.5)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 20)
    4 (4 to 19)
        CD40L-/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)
    4 (4 to 13)
    38 (4 to 98)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 19)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L-/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)
    4 (4 to 199.5)
    4 (4 to 73)
    4 (4 to 47)
    30 (4 to 286)
    4 (4 to 37)
    4 (4 to 45)
        CD40L-/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)
    50 (30.5 to 101)
    4 (4 to 5)
    32 (4 to 109)
    4 (4 to 284)
    4 (4 to 104)
    9 (4 to 102)
        CD40L-/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    4 (4 to 4)
    4 (4 to 107)
    91.5 (4 to 1024)
    4 (4 to 39)
    4 (4 to 73)
        CD40L-/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)
    41 (4 to 66)
    4 (4 to 53)
    28.5 (4 to 285)
    28 (4 to 228)
    4 (4 to 30)
    4 (4 to 85)
        CD40L-/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)
    19 (4 to 144)
    35 (4 to 66)
    29 (4 to 149)
    58 (4 to 432)
    4 (4 to 39)
    4 (4 to 45)
        CD40L-/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)
    51 (4 to 264)
    4 (4 to 4)
    4 (4 to 184)
    4 (4 to 101)
    4 (4 to 27)
    4 (4 to 30.5)
        CD40L-/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)
    21 (4 to 80)
    4 (4 to 61)
    4 (4 to 36)
    7.5 (4 to 37)
    25.5 (4 to 57)
    4 (4 to 18)
        CD40L-/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)
    17 (4 to 61)
    4 (4 to 5)
    4 (4 to 59)
    4 (4 to 82)
    20.5 (4 to 39)
    4 (4 to 27)
        CD40L-/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)
    4 (4 to 4)
    80 (4 to 156)
    4 (4 to 67.5)
    47.5 (6 to 123)
    20.5 (4 to 67)
    24.5 (4 to 71)
        CD40L-/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)
    40 (4 to 128)
    4 (4 to 69)
    36.5 (4 to 112)
    4 (4 to 43)
    4 (4 to 27)
    5 (4 to 64)
        CD40L-/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)
    16 (4 to 54)
    4 (4 to 4)
    4 (4 to 89)
    18.5 (4 to 90)
    20 (4 to 56)
    4.5 (4 to 30)
        CD40L-/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)
    4 (4 to 4)
    4 (4 to 8)
    4 (4 to 4)
    4 (4 to 42)
    4 (4 to 60)
    4 (4 to 29)
    No statistical analyses for this end point

    Secondary: Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.

    Close Top of page
    End point title
    Frequency of M72-specific CD8+ T cells per million cells expressing any combination of immune markers.
    End point description
    Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).
    End point type
    Secondary
    End point timeframe
    Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)
    End point values
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Number of subjects analysed
    6
    3
    18
    22
    37
    36
    Units: T cells/million cells
    median (inter-quartile range (Q1-Q3))
        CD40L-/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)
    54.5 (25.5 to 821)
    6 (4 to 95)
    70 (12 to 541)
    216.5 (57 to 1831)
    54.5 (4 to 159)
    78.5 (25 to 349)
        CD40L-/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)
    89 (36.5 to 893.5)
    9 (4 to 31)
    152 (4 to 575)
    205 (90 to 1660)
    69.5 (43 to 830)
    90.5 (4.5 to 484.5)
        CD40L-/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)
    96 (26 to 163)
    118 (4 to 232)
    127.5 (13 to 327.5)
    386.5 (27 to 1969.5)
    64.5 (4 to 438)
    151.5 (28 to 467)
        CD40L-/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)
    48 (4 to 78)
    33 (4 to 81)
    100.5 (48 to 326)
    229 (4 to 1022)
    46.5 (4 to 179)
    83.5 (4 to 335)
        CD40L-/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)
    147.5 (55 to 824.5)
    4 (4 to 4)
    70 (4 to 1116)
    172 (18 to 1492)
    13 (4 to 65)
    59 (4 to 310)
        CD40L-/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)
    286.5 (48 to 469)
    4 (4 to 59)
    51 (4 to 245)
    85 (4 to 628)
    69 (4 to 233)
    60 (22 to 232.5)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Solicited symptoms: During the 7 day (Days 0-6), after each vaccine dose, unsolicited AEs: During the 30 day (Days 0-29) after vaccination, SAEs: Up to day 210
    Adverse event reporting additional description
    Results presented per group consist of a summary of the events (SAEs and AEs other than SAEs, respectively) reported, compiling overall number of subjects with events across the different periods of assessment.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    18.0
    Reporting groups
    Reporting group title
    TB Treatment GSK 692342 Group
    Reporting group description
    Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Treatment Saline Group
    Reporting group description
    Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Treated GSK 692342 Group
    Reporting group description
    Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1

    Reporting group title
    TB Treated Saline Group
    Reporting group description
    Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Naive GSK 692342 Group
    Reporting group description
    Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.

    Reporting group title
    TB Naive Saline Group
    Reporting group description
    Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.

    Serious adverse events
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    2 / 24 (8.33%)
    2 / 25 (8.00%)
    1 / 40 (2.50%)
    0 / 40 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    Immune system disorders
    Hypersensitivity
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    1 / 24 (4.17%)
    0 / 25 (0.00%)
    0 / 40 (0.00%)
    0 / 40 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Anal fistula
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    0 / 24 (0.00%)
    0 / 25 (0.00%)
    1 / 40 (2.50%)
    0 / 40 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhoids
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    0 / 24 (0.00%)
    0 / 25 (0.00%)
    1 / 40 (2.50%)
    0 / 40 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Calculus ureteric
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    0 / 24 (0.00%)
    1 / 25 (4.00%)
    0 / 40 (0.00%)
    0 / 40 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Calculus urinary
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    1 / 24 (4.17%)
    0 / 25 (0.00%)
    0 / 40 (0.00%)
    0 / 40 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydronephrosis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    0 / 24 (0.00%)
    1 / 25 (4.00%)
    0 / 40 (0.00%)
    0 / 40 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    0 / 24 (0.00%)
    1 / 25 (4.00%)
    0 / 40 (0.00%)
    0 / 40 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    TB Treatment GSK 692342 Group TB Treatment Saline Group TB Treated GSK 692342 Group TB Treated Saline Group TB Naive GSK 692342 Group TB Naive Saline Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    6 / 7 (85.71%)
    2 / 6 (33.33%)
    22 / 24 (91.67%)
    8 / 25 (32.00%)
    39 / 40 (97.50%)
    10 / 40 (25.00%)
    Investigations
    Hepatic enzyme increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    2 / 24 (8.33%)
    0 / 25 (0.00%)
    0 / 40 (0.00%)
    0 / 40 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    Nervous system disorders
    Headache
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    0 / 24 (0.00%)
    0 / 25 (0.00%)
    2 / 40 (5.00%)
    0 / 40 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    General disorders and administration site conditions
    Pain
         subjects affected / exposed
    6 / 7 (85.71%)
    1 / 6 (16.67%)
    22 / 24 (91.67%)
    3 / 25 (12.00%)
    39 / 40 (97.50%)
    8 / 40 (20.00%)
         occurrences all number
    6
    1
    22
    3
    39
    8
    Redness
         subjects affected / exposed
    3 / 7 (42.86%)
    0 / 6 (0.00%)
    8 / 24 (33.33%)
    0 / 25 (0.00%)
    10 / 40 (25.00%)
    0 / 40 (0.00%)
         occurrences all number
    3
    0
    8
    0
    10
    0
    Swelling
         subjects affected / exposed
    3 / 7 (42.86%)
    0 / 6 (0.00%)
    6 / 24 (25.00%)
    1 / 25 (4.00%)
    11 / 40 (27.50%)
    0 / 40 (0.00%)
         occurrences all number
    3
    0
    6
    1
    11
    0
    Fatigue
         subjects affected / exposed
    3 / 7 (42.86%)
    2 / 6 (33.33%)
    17 / 24 (70.83%)
    8 / 25 (32.00%)
    36 / 40 (90.00%)
    10 / 40 (25.00%)
         occurrences all number
    3
    2
    17
    8
    36
    10
    Gastrointestinal symptoms
         subjects affected / exposed
    2 / 7 (28.57%)
    0 / 6 (0.00%)
    10 / 24 (41.67%)
    4 / 25 (16.00%)
    16 / 40 (40.00%)
    6 / 40 (15.00%)
         occurrences all number
    2
    0
    10
    4
    16
    6
    Headache (solicited)
         subjects affected / exposed
    3 / 7 (42.86%)
    1 / 6 (16.67%)
    18 / 24 (75.00%)
    4 / 25 (16.00%)
    24 / 40 (60.00%)
    6 / 40 (15.00%)
         occurrences all number
    3
    1
    18
    4
    24
    6
    Malaise
         subjects affected / exposed
    3 / 7 (42.86%)
    2 / 6 (33.33%)
    16 / 24 (66.67%)
    6 / 25 (24.00%)
    35 / 40 (87.50%)
    9 / 40 (22.50%)
         occurrences all number
    3
    2
    16
    6
    35
    9
    Myalgia
         subjects affected / exposed
    3 / 7 (42.86%)
    1 / 6 (16.67%)
    18 / 24 (75.00%)
    5 / 25 (20.00%)
    34 / 40 (85.00%)
    7 / 40 (17.50%)
         occurrences all number
    3
    1
    18
    5
    34
    7
    Temperature/(Axillary)
         subjects affected / exposed
    4 / 7 (57.14%)
    1 / 6 (16.67%)
    10 / 24 (41.67%)
    0 / 25 (0.00%)
    17 / 40 (42.50%)
    0 / 40 (0.00%)
         occurrences all number
    4
    1
    10
    0
    17
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    3 / 24 (12.50%)
    0 / 25 (0.00%)
    0 / 40 (0.00%)
    0 / 40 (0.00%)
         occurrences all number
    0
    0
    3
    0
    0
    0
    Infections and infestations
    Upper respiratory tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    3 / 24 (12.50%)
    0 / 25 (0.00%)
    4 / 40 (10.00%)
    3 / 40 (7.50%)
         occurrences all number
    0
    0
    3
    0
    4
    3
    Gastroenteritis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    0 / 24 (0.00%)
    0 / 25 (0.00%)
    2 / 40 (5.00%)
    1 / 40 (2.50%)
         occurrences all number
    0
    0
    0
    0
    2
    1
    Nasopharyngitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    2 / 24 (8.33%)
    0 / 25 (0.00%)
    1 / 40 (2.50%)
    0 / 40 (0.00%)
         occurrences all number
    0
    0
    2
    0
    1
    0
    Urinary tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    0 / 7 (0.00%)
    0 / 6 (0.00%)
    2 / 24 (8.33%)
    0 / 25 (0.00%)
    0 / 40 (0.00%)
    0 / 40 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    14 May 2012
    • At the European Medicines Agency’s (EMA) request, GSK Biologicals has updated its procedure for emergency unblinding during the conduct of a clinical study. According to the revised procedure, the responsibility and the decision to break the treatment code in emergency situations resides solely with the investigator and consequently, the investigator will have full authority to break the treatment code. • Change in the number of participating countries in this study. • It has been clarified that TB treatment for subjects belonging to the TB-treatment cohort will be provided independent of this study. • Additional minor modifications have been implemented.
    18 Feb 2013
    This amendment aims to correct the centre-specific information provided in the protocol. However, as centre-specific information is available in other documents included in the clinical trial application, it was decided to remove centre-specific information from the protocol to avoid future amendments in case enrolment of subjects in the TB treated and TB treatment cohorts remains difficult and additional centres/countries might need to be added to the study.
    16 Jan 2014
    Due to a safety signal identified in the TB treatment cohort (increased local solicited symptoms post-dose 2), the protocol was amended to include exploratory testing on blood samples taken at Days 0, 7, 30, 37, 60 and 210.

    Interruptions (globally)

    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    10 Apr 2014
    A safety signal was observed during a planned interim safety review. In consequence the trial was put on hold. After careful consideration further conduct of this safety study is not considered the best course of action and enrolment in the study was terminated.
    -

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA